Drug General Information (ID: DDITVDQ271)
Drug Name			Bumetanide		Drug Info		Amisulpride		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Diuretics				Antipsychotic Agents
Structure

Mechanism of Bumetanide-Amisulpride Interaction (Severity Level: Moderate)
Increased risk of ventricular arrhythmias Click to Show/Hide Mechanism Graph
Drug Name		Bumetanide				Amisulpride
Mechanism 1		Hypokalemia				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		Ventricular arrhythmias
		Factor Description		Ventricular arrhythmias are abnormal heart rhythms that cause your heart's lower chambers to pump blood instead of pumping it. This can limit or stop your heart from supplying blood to your body. While some of these arrhythmias are harmless and do not cause symptoms, others can have serious, even fatal, effects on your body.
Mechanism Description		Increased risk of ventricular arrhythmias by the combination of Bumetanide and Amisulpride
Mechanism 2		Hypomagnesemia				Prolong QT interval
Key Mechanism Factor 2
		Factor Name		Ventricular arrhythmias
		Factor Description		Ventricular arrhythmias are abnormal heart rhythms that cause your heart's lower chambers to pump blood instead of pumping it. This can limit or stop your heart from supplying blood to your body. While some of these arrhythmias are harmless and do not cause symptoms, others can have serious, even fatal, effects on your body.
Mechanism Description		Increased risk of ventricular arrhythmias by the combination of Bumetanide and Amisulpride

Recommended Action
Management		Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".